These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 12897641)
1. Adjuvant topiramate administration: a pharmacologic strategy for addressing NMDA receptor hypofunction in schizophrenia. Deutsch SI; Schwartz BL; Rosse RB; Mastropaolo J; Marvel CL; Drapalski AL Clin Neuropharmacol; 2003; 26(4):199-206. PubMed ID: 12897641 [TBL] [Abstract][Full Text] [Related]
2. Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication. Drapalski AL; Rosse RB; Peebles RR; Schwartz BL; Marvel CL; Deutsch SI Clin Neuropharmacol; 2001; 24(5):290-4. PubMed ID: 11586114 [TBL] [Abstract][Full Text] [Related]
3. Topiramate antagonizes MK-801 in an animal model of schizophrenia. Deutsch SI; Rosse RB; Billingslea EN; Bellack AS; Mastropaolo J Eur J Pharmacol; 2002 Aug; 449(1-2):121-5. PubMed ID: 12163115 [TBL] [Abstract][Full Text] [Related]
4. Effect of topiramate augmentation in chronic schizophrenia: a placebo-controlled trial. Behdani F; Hebrani P; Rezaei Ardani A; Rafee E Arch Iran Med; 2011 Jul; 14(4):270-5. PubMed ID: 21726104 [TBL] [Abstract][Full Text] [Related]
5. Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials. Correll CU; Maayan L; Kane J; Hert MD; Cohen D J Clin Psychiatry; 2016 Jun; 77(6):e746-56. PubMed ID: 27337425 [TBL] [Abstract][Full Text] [Related]
6. A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. Roy Chengappa K; Kupfer DJ; Parepally H; John V; Basu R; Buttenfield J; Schlicht P; Houck P; Brar JS; Gershon S Bipolar Disord; 2007 Sep; 9(6):609-17. PubMed ID: 17845276 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. Gobbi G; Gaudreau PO; Leblanc N J Clin Psychopharmacol; 2006 Oct; 26(5):467-73. PubMed ID: 16974186 [TBL] [Abstract][Full Text] [Related]
8. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Muscatello MR; Bruno A; Pandolfo G; Micò U; Bellinghieri PM; Scimeca G; Cacciola M; Campolo D; Settineri S; Zoccali R J Psychopharmacol; 2011 May; 25(5):667-74. PubMed ID: 20615930 [TBL] [Abstract][Full Text] [Related]
9. Psychotic symptoms associated with topiramate: cognitive side effects or worsening of psychosis? Duggal HS J Clin Psychiatry; 2004 Aug; 65(8):1145; author reply 1145--6. PubMed ID: 15323603 [No Abstract] [Full Text] [Related]
10. The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Lee S; Sziklas V; Andermann F; Farnham S; Risse G; Gustafson M; Gates J; Penovich P; Al-Asmi A; Dubeau F; Jones-Gotman M Epilepsia; 2003 Mar; 44(3):339-47. PubMed ID: 12614389 [TBL] [Abstract][Full Text] [Related]
11. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. Afshar H; Roohafza H; Mousavi G; Golchin S; Toghianifar N; Sadeghi M; Talaei M J Psychopharmacol; 2009 Mar; 23(2):157-62. PubMed ID: 18515465 [TBL] [Abstract][Full Text] [Related]
12. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. Dursun SM; Deakin JF J Psychopharmacol; 2001 Dec; 15(4):297-301. PubMed ID: 11769825 [TBL] [Abstract][Full Text] [Related]
13. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Aldenkamp AP; Baker G; Mulder OG; Chadwick D; Cooper P; Doelman J; Duncan R; Gassmann-Mayer C; de Haan GJ; Hughson C; Hulsman J; Overweg J; Pledger G; Rentmeester TW; Riaz H; Wroe S Epilepsia; 2000 Sep; 41(9):1167-78. PubMed ID: 10999556 [TBL] [Abstract][Full Text] [Related]
14. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Swainston Harrison T; Perry CM Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633 [TBL] [Abstract][Full Text] [Related]
15. Aripiprazole plus topiramate in opioid-dependent patients with schizoaffective disorder: an 8-week, open-label, uncontrolled, preliminary study. Bruno A; Romeo VM; Pandolfo G; Scimeca G; Zoccali RA; Muscatello MR Subst Abus; 2014; 35(2):119-21. PubMed ID: 24821345 [TBL] [Abstract][Full Text] [Related]
16. [Effectiveness and safety of topiramate in treatment-resistant bipolar disorder]. Vieta E; Gilabert A; Rodríguez A; García-Castrillón A; Luna MJ; Arrufat E; García-Parés G Actas Esp Psiquiatr; 2001; 29(3):148-52. PubMed ID: 11412488 [TBL] [Abstract][Full Text] [Related]
17. 1-year follow-up of patients treated with risperidone and topiramate for a manic episode. Vieta E; Goikolea JM; Olivares JM; González-Pinto A; Rodriguez A; Colom F; Comes M; Torrent C; Sánchez-Moreno J J Clin Psychiatry; 2003 Jul; 64(7):834-9. PubMed ID: 12934986 [TBL] [Abstract][Full Text] [Related]
18. Differential cognitive and behavioral effects of topiramate and valproate. Meador KJ; Loring DW; Hulihan JF; Kamin M; Karim R; Neurology; 2003 May; 60(9):1483-8. PubMed ID: 12743236 [TBL] [Abstract][Full Text] [Related]
19. Topiramate augmentation in clozapine-treated patients with schizophrenia: clinical and metabolic effects. Hahn MK; Remington G; Bois D; Cohn T J Clin Psychopharmacol; 2010 Dec; 30(6):706-10. PubMed ID: 21105286 [TBL] [Abstract][Full Text] [Related]
20. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine]. Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L Encephale; 2001; 27(1):53-9. PubMed ID: 11294039 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]